Kalvista Pharmaceuticals, INC Form 4 insider transactions

KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, sold 1,480 shares of common stock to cover tax withholding obligations following the vesting of 5,000 restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, acquired 3,125 shares through RSU vesting and subsequently sold 1,954 shares to cover tax obligations.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 2,336 shares of common stock to cover tax withholding obligations following the vesting of 5,000 restricted stock units.

KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, sold 1,864 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of 3,750 restricted stock units and a subsequent sale of 2,362 shares to cover tax obligations.

KalVista Pharmaceuticals CEO Benjamin Palleiko sold 10,940 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 2,942 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 2,649 shares of common stock to cover tax withholding obligations related to RSU vesting.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax obligations.

KalVista Pharmaceuticals CEO Benjamin Palleiko sold shares to cover tax obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko was granted 113,920 Restricted Stock Units and 113,920 employee stock options.

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, acquired 87,500 shares of common stock through the vesting of performance stock units due to achieved performance metrics, subsequently selling 32,979 shares to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of 60,000 performance stock units and a subsequent sale of 30,250 shares to cover tax withholding obligations.

KalVista Pharmaceuticals' CEO and Director, Benjamin L. Palleiko, reported the acquisition of 15,625 shares of common stock through RSU vesting and the subsequent sale of 7,169 shares to cover tax obligations.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, acquired 5,000 shares of common stock through RSU vesting and subsequently sold 2,146 shares to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding obligations.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction to satisfy tax obligations.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of 3,750 restricted stock units and a subsequent sale of 2,317 shares to cover tax withholding obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported the acquisition of 23,250 shares of common stock from restricted stock unit vesting and the subsequent sale of 9,999 shares to cover tax obligations.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

CEO Benjamin Palleiko reports the vesting of restricted stock units and performance stock units, along with sales to cover tax obligations.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports the vesting and sale of shares to cover tax obligations.

Venrock Healthcare Capital Partners III, L.P. reports purchasing 25,000 shares of KalVista Pharmaceuticals, Inc. common stock at a weighted average price of $9.42 on April 9, 2025, increasing their total holdings.

CEO Benjamin Palleiko reports acquisition and disposal of KalVista Pharmaceuticals stock to cover tax obligations related to vesting of restricted stock units.

Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of company stock and restricted stock units.

Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals, acquired 372,000 restricted stock units on February 21, 2025, according to a recent SEC filing.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting RSUs.

Brian Piekos, CFO of KalVista Pharmaceuticals, reports the acquisition of 80,000 restricted stock units (RSUs) on February 21, 2025, according to a Form 4 filing with the SEC.

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Chief Medical Officer Paul K. Audhya of KalVista Pharmaceuticals reports the vesting of restricted stock units and performance stock units, along with sales to cover tax obligations.